On November 5th, , President of North America at Ori Biotech, joined Bruce Thompson from Kincell Bio, Amy Hay from CTMC, and John Lunger former Chief Patient Supply Officer at Adaptimmune to examine the financial and operational realities shaping the path from early development to commercial manufacturing.
The session explored how the promise of wider access to cell and gene therapies depends on developers’ ability to bring products to market under growing cost pressures. As demand rises, understanding total cost of ownership has become essential for making early decisions that won’t constrain scale-up later.
The speakers discussed hidden costs that often go unaccounted for, how early process design choices can influence or strain commercial expansion, the practical trade-offs between automation and flexibility, and approaches for evaluating TCO across clinical and commercial stages.
By grounding the conversation in real-world experience, the panel highlighted how developers can build manufacturing strategies that remain scientifically sound and economically durable as programmes advance.